Personalized Medicine’s 20th Anniversary: From Promise to Practice
November 30 – December 1, 2023 • Ritz-Carlton Laguna Niguel, Dana Point, CA
Reflections and Visions
SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine CoalitionLEARN MORE
For many Americans, Scott Gottlieb has become a household name in health care. He is a former commissioner of the Food and Drug Administration. He made frequent media appearances during the Covid-19 pandemic. And in 2019, he oversaw a record number of new personalized medicine approvals. During this opening keynote address, Gottlieb will reveal his latest thinking about the future of personalized medicine and discuss what it needs to advance.
INTRODUCTION | Lauren Silvis, J.D., Senior Vice President, External Affairs, Tempus
KEYNOTE SPEAKER | Scott Gottlieb, M.D., Senior Fellow, American Enterprise Institute; New York Times best-selling author, Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next PandemicLEARN MORE
Game-changing early detection technologies. Wearable health monitoring devices. Gene editing. Investors see tantalizing possibilities in personalized medicine. But the path to profitability is fraught with challenges. During this session, a panel of investors will consider the future of investment in personalized medicine.
MODERATOR | Jared Whitlock, Features Editor, Endpoints News
Vineeta Agarwala, M.D., Ph.D., General Partner, Andreessen Horowitz
Tess Cameron, Principal, RA Capital Management
Michael J. Pellini, M.D., Managing Partner, Section 32LEARN MORE
Many companies are widening the frontiers of personalized medicine. PathAI is using artificial intelligence to advance personalized medicine in pathology. Siemens executives see an expanded role for imaging biomarkers to target therapies to those who will benefit. DNAnexus is using cloud-based computing platforms to inform the development of more precise medical interventions. And at Kyverna Therapeutics, scientists are exploring how to extend the benefits of cell-based immunotherapies to patients with autoimmune diseases. During this session, executives from each of these companies will explain how their work may expand the boundaries of personalized medicine.
MODERATOR | Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School
Andy Beck, M.D., Ph.D., CEO, PathAI
Peter Maag, Ph.D., CEO, Kyverna Therapeutics
Rangarajan Sampath, Ph.D., Senior Vice President, Head of Center for Innovation in Diagnostics, Siemens Healthineers
Omar Serang, Chief Cloud Officer, DNAnexus
The Annual Award for Leadership in Personalized Medicine recognizes an individual whose contributions in science, business, and policy have helped advance the frontiers of the field. This year’s award goes to Bonnie J. Addario, a tireless patient advocate and co-founder of GO2 for Lung Cancer.
PRESENTER | Michael J. Pellini, M.D., Managing Partner, Section 32
AWARDEE | Bonnie J. Addario, Co-Founder, GO2 for Lung CancerLEARN MORE
Innovators in personalized medicine are struggling to convince health insurance executives that paying more for tests and treatments today will decrease health spending in the future by keeping patients healthier, longer. While serving as Chief Medical Officer for regional health insurer Point32Health from 2011 to March of 2023, Michael Sherman repeatedly broke this bottleneck by signing innovative reimbursement agreements with diagnostics and therapeutics developers who are willing to share in the financial risks of piloting coverage for new medical products. During this session, Sherman will reflect on what it takes to move the reimbursement needle in ways that benefit both patients and health systems.
INTRODUCTION | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition
SPEAKER | Michael Sherman, M.D., Venture Partner, RA Capital ManagementLEARN MORE
Diagnostics companies provide a backbone for personalized medicine by developing the tests necessary to target the right preventive and treatment interventions to the right patients at the right times. Testing innovators today face daunting challenges along with promising new opportunities to impact health care. During this panel discussion, industry executives will consider the future of diagnostic test development.
MODERATOR | Kimberly Popovits, Former Chairman, CEO, Genomic Health
Brian Alexander, M.D., CEO, Foundation Medicine
Helmy Eltoukhy, Ph.D., Chairman, co-CEO, Guardant Health
Chad Robins, Chairman, CEO, Adaptive Biotechnologies
Jay G. Wohlgemuth, M.D., Former Chief Medical Officer & Chief Scientific Officer, Quest Diagnostics; Managing Partner, Trusted Health AdvisorsLEARN MORE
The pharmaceutical industry stands four-square behind personalized medicine. PMC’s latest research shows that personalized medicines accounted for at least 25 percent of new U.S. Food and Drug Administration-approved drugs for each of the last eight years. But economic and political landscapes are shifting. During this panel discussion, industry executives will discuss how they are continuing to cultivate their pipelines while adapting to dynamic circumstances across the globe.
MODERATOR | Randy Burkholder, Vice President, Policy and Research, PhRMA
Gabriele Allegri, Global Commercial Head, Precision Medicine, The Janssen Pharmaceutical Companies of Johnson & Johnson
Sarah Hersey, Vice President, Precision Medicine, Bristol Myers Squibb
Steffan Ho, M.D., Ph.D., Vice President, Head of Translational Oncology and Oncology Diagnostics, Pfizer
Tamar Thompson, Vice President, Head of Corporate Affairs, Alexion/AstraZeneca Rare DiseaseLEARN MORE
Leaders in clinical care are eager to understand whether clinical integration programs in personalized medicine will improve the lives of their patients. During this presentation, the Personalized Medicine Coalition will unveil the preliminary results of a study designed to evaluate whether the clinical integration efforts of United States health systems that score higher on a peer-reviewed survey measuring multi-factorial clinical adoption of personalized medicine are driving superior clinical outcomes for their patients.
MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition
Gary Gustavsen, Partner, Health Advances
For clinical care providers, personalized medicine may present opportunities to improve care for their patients and make better use of scare resources by targeting treatments to those who will benefit. But spearheading the clinical adoption of personalized medicine is anything but easy. During this panel discussion, researchers, business leaders, and clinicians who are intimately involved in the clinical integration of personalized medicine will reflect on the pace of progress in the United States and Europe.
MODERATOR | Howard McLeod, Pharm.D., Managing Director, Clarified Precision Medicine
Antonio L. Andreu, M.D., Ph.D., Scientific Director, European Infrastructure for Translational Medicine (EATRIS)
Thomas Brown, M.D., Chief Medical Officer, Syapse
Catherine Hajek, M.D., Medical Director, Helix; Director, Population Genomics, Sanford Health
Konstantinos Lazaridis, M.D., Executive Director, Center for Individualized Medicine, Mayo ClinicLEARN MORE
As a Chief Medical Officer responsible for the health care business of one of the world’s largest technology companies, Amy Abernethy, formerly Principal Deputy Commissioner at the U.S. Food and Drug Administration, sits at the intersection of the rapidly converging industries of medicine, technology, and digital health. During this closing keynote address, Abernethy will explain her vision of a future in which collaborative leaders deploy advanced computational tools, artificial intelligence, and remote data collection technologies to unleash the full potential of personalized medicine for every patient.
INTRODUCTION | Michael Vasconcelles, M.D., Chief Medical Officer, ImmunoGen
KEYNOTE SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, President, Product Development, Verily, an Alphabet companyLEARN MORE
Executing in a New Era
SPEAKER | Lincoln Nadauld, M.D., Ph.D., President, CEO, Culmination Bio
As the CEO of the pharmaceutical industry’s leading trade association, Stephen Ubl is helping industry executives shape and navigate shifting scientific, economic, and political landscapes in Washington and around the world. During this keynote interview with Washington Post Associate Editor Karen Tumulty, Ubl will share his perspective on the future prospects for personalized medicine and innovative drug development in 2024 and beyond.
MODERATOR | Karen Tumulty, Associate Editor, The Washington Post
KEYNOTE SPEAKER | Stephen J. Ubl, President, CEO, PhRMALEARN MORE
As a company whose diagnostic tests, drug development services, and technological solutions touch the care trajectories of more than 120 million patients across more than 100 countries each year, Labcorp’s thinking about the future of health and medicine will have a profound impact on the contours of patient care for years to come. Labcorp CEO Adam Schechter will share his perspective on the future of personalized medicine and the diagnostics industry.
KEYNOTE SPEAKER | Adam Schechter, Chairman, President, CEO, Labcorp
When it comes to medicine, no one knows better than patients that one size does not fit all. During this wide-ranging fireside chat with Karen Tumulty of The Washington Post, Kathy Giusti, a two-time cancer survivor and the Founder of the Multiple Myeloma Research Foundation, will reflect on the status of health care in America.
MODERATOR | Karen Tumulty, Associate Editor, The Washington Post
Kathy Giusti, Founder, Multiple Myeloma Research Foundation
By giving physicians an easy way to detect early-stage cancers anywhere in the body, blood-based multi-cancer early detection (MCED) tests might help physicians and patients get ahead of a disease that is the second-leading cause of death in the United States today. But it could take years of research to confirm their clinical and economic benefits. In this context, researchers and industry executives will close the conference with a discussion about when and how one of the most promising tools shaping thinking about the future of personalized medicine should be integrated into health care to benefit patients with little time to waste.
MODERATOR | Lincoln Nadauld, M.D., Ph.D., President, CEO, Culmination Bio
Tomasz Beer, M.D., Vice President, Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences
Josh Ofman, M.D., President, Grail
Kathryn Phillips, Ph.D., Professor, Founding Director of the Center for Translational and Policy Research on Precision Medicine, University of California, San Francisco
Wendy Rubinstein, M.D., Ph.D., Senior Scientist, Division of Cancer Prevention, National Cancer InstituteLEARN MORE
SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition